Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Comparison of
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03604757 (Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Prostate Cancer of Various Metastatic Risks Candidates for Radical Prostatectomy - "UROPET"), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Prostate Cancer of Various Metastatic Risks Candidates for Radical Prostatectomy - "UROPET"
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis.Annals of nuclear medicine · 2024Pooled it
- Dual-tracer PET/CT with [European journal of nuclear medicine and molecular imaging · 2026Trial
- GRPR-Targeted Radionuclide Conjugates: A Molecular Evolution Perspective.Chemistry & biodiversity · 2026Review
- Single-Domain Antibody Probe with Low Renal Uptake for Claudin 18.2-Targeted PET Imaging of Gastric Cancer: Preclinical and Pilot Clinical Evaluations.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Prospective head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET-directed radiotherapy for prostate cancer: From precision planning to future innovations.View (Beijing, China) · 2026Article
- Diagnostic performance of gastrin-releasing peptide receptor-targeted positron-emission tomography in biochemically recurrent prostate cancer-a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- The additive value ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- GRPR-induced FAM135A expression promote perineural invasion in prostate cancer.Molecular cancer · 2025Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- The evolving role of positron emission tomography in precision prostate cancer biopsy.European journal of clinical investigation · 2025Review
- RM2 and DB15 analogues bearing [EJNMMI radiopharmacy and chemistry · 2025Article
- Development of Novel Gastrin-Releasing Peptide Receptor-Targeted Radioligand with Albumin Binder to Improve Accumulation in Tumor.ACS medicinal chemistry letters · 2025Article
- Design and Synthesis ofChemMedChem · 2025Article
- Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study).EJNMMI research · 2025Article
- Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.Journal of Zhejiang University. Science. B · 2025Review
- Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis.EJNMMI research · 2024Article
- Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the wide range of therapeutic options for localized prostate cancer (e.g., active surveillance, radiation-beam therapy, focal therapy, and radical prostatectomy), accurate assessment of the aggressiveness and localization of primary prostate cancer lesions is essential for treatment decision making. National Comprehensive Cancer Network guidelines recognize prostate-specific membrane antigen (PSMA) PET/CT for use in initial staging of high-risk primary prostate cancer. The gastrin-releasing peptide receptor (GRP-R) is a neuropeptide receptor overexpressed by low-risk prostate cancer cells. We aimed to perform the first (to our knowledge) prospective head-to-head comparison of PSMA- and GRP-R-targeted imaging at initial staging to understand how PSMA PET and GRP-R PET can be used or combined in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.